Key terms
About Lonza Finance International Naamloze vennootschap 3.5% 04-SEP-2034
Sector
Finance
Industry
Finance/Rental/Leasing
Home page
ISIN
BE6355215664
FIGI
BBG01PHHR4P2
Part of Lonza Group AG, Lonza Finance International NV is a contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceutical and pharmaceutical technologies. The company is based in Bornem, Belgium. Lonza Finance International offers integrated end-to-end services including early development, process and analytical development, cGMP manufacturing, and commercialization support across modalities such as biologics, small molecules, highly potent APIs, microbial fermentation, lipid nanoparticles, and specialized areas like cell and gene therapies. Its capabilities include viral vector manufacturing for gene therapies, scalable GMP bioreactor microbial drug substance production, and advanced pharmaceutical method development for small molecules. The Belgian company also provides drug product development tailored to specific populations, multiparticulate technologies, taste and odor masking, and delivery systems such as microdosing and modified release formulations. Facilities support clinical trial material manufacturing, clinical supply services, and regulatory affairs. Lonza Finance International integrates sustainability into its operations, targeting reductions in greenhouse gas emissions, water use, and waste generation. The company was founded in 2019.
Related bonds
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.